Case report · 10 Aug 2026
Research articlePublished 23 Mar 2022
UC-IIandreg; Undenatured Type II Collagen Reduces Knee Joint Discomfort and Improves Mobility in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled Clinical Study
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Joint discomfort is a common issue in athletes and healthy, active individuals. The objective of this study was to evaluate the efficacy of UC-II® undenatured type II collagen (Undenatured Collagen) in managing knee joint discomfort and mobility in healthy subjects with Activity-related Joint Discomfort (ArJD). Subjects who reported knee pain of 5 on an 11-point Likert scale while performing a Single-Leg-Step-Down (SLSD) test were randomized to receive placebo (PLA, n=48), or Undenatured Collagen (n=48) for 24 weeks. Joint mobility was measured from the daily step number. Joint discomfort was evaluated using the Knee Injury and Osteoarthritis Outcome Score (KOOS) questionnaire, duration of pain during sporting activities and number of steps to reach defined pain levels during the SLSD test. A sub-analysis by gender showed a higher number of daily steps in males from the Undenatured Collagen group versus PLA (p=0.0374) after 24 weeks. In the SLSD test, the Undenatured Collagen group showed a significant change over time and baseline in the number of repetitions to reach pain 2 (p<0.05). Subjects in Undenatured Collagen group of 20-35 years old took more steps on the SLSD test before reporting the pain 5. A significant change over baseline for the pain duration after sports was further observed in 20-35 years old subjects (p<0.05). Analysis of KOOS demonstrated an improvement of subscale function in sport and recreation over time (p=0.0009) and of subscale quality of life over baseline (p<0.05) in the Undenatured Collagen group. In conclusion, the data suggests Undenatured Collagen reduces joint discomfort and improves mobility.
Keywords
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Clinical Trials.
Short communication · 31 Jul 2026
Understanding Bioavailability as a Key Element in Effective Therapeutic Delivery
Research article · 14 Jun 2026
Ensuring Rights and Dignity in Ethical Practices of Clinical Studies with Vulnerable Group and Safeguarding Vulnerable Group Act (2006)
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Clinical Trials
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Katharina Knaub”
- BylineArticles whose byline prints “Christiane Schön”
- BylineArticles whose byline prints “Wilfried Alt”
- BylineArticles whose byline prints “Shane Durkee”
- BylineArticles whose byline prints “Zainulabedin Saiyed”
- BylineArticles whose byline prints “Vijaya Juturu”
